In yesterday’s Wall Street session, Agile Therapeutics Inc. (NASDAQ:AGRX) shares traded at $0.19, up 0.05% from the previous session.
AGRX stock price is now -29.79% away from the 50-day moving average and -93.90% away from the 200-day moving average. The market capitalization of the company currently stands at $8.22M.
, while ‘Maxim Group’ rates the stock as ‘Buy’.
In other news, ALTOMARI ALFRED, Chief Executive Officer bought 50,000 shares of the company’s stock on Aug 26. The stock was bought for $22,500 at an average price of $0.45. Upon completion of the transaction, the Chief Executive Officer now directly owns 64,343 shares in the company, valued at $12225.17. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AGRX stock. A new stake in Agile Therapeutics Inc. shares was purchased by LPL FINANCIAL LLC during the first quarter worth $80,000. ADVISORY SERVICES NETWORK, LLC invested $15,000 in shares of AGRX during the first quarter. In the first quarter, NORTHERN TRUST CORP acquired a new stake in Agile Therapeutics Inc. valued at approximately $10,000. SABBY MANAGEMENT, LLC acquired a new stake in AGRX for approximately $10,000. WARBERG ASSET MANAGEMENT LLC purchased a new stake in AGRX valued at around $3,000 in the second quarter. In total, there are 28 active investors with 5.70% ownership of the company’s stock.
Wednesday morning saw Agile Therapeutics Inc. (NASDAQ: AGRX) opened at $0.1954. During the past 12 months, Agile Therapeutics Inc. has had a low of $0.18 and a high of $29.60. As of last week, the company has a debt-to-equity ratio of 0.21, a current ratio of 1.30, and a quick ratio of 1.20. The fifty day moving average price for AGRX is $0.2763 and a two-hundred day moving average price translates $3.1831 for the stock.
The latest earnings results from Agile Therapeutics Inc. (NASDAQ: AGRX) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$2.71, beating analysts’ expectations of -$3.7 by 0.99. This compares to -$7.16 EPS in the same period last year. The company reported revenue of $3.0 million for the quarter, compared to $1.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 133.26 percent. For the current quarter, analysts expect AGRX to generate $2.33M in revenue.
Agile Therapeutics Inc.(AGRX) Company Profile
Agile Therapeutics, Inc., a women’s healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.